Compare JACK & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JACK | TARA |
|---|---|---|
| Founded | 1951 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.3M | 292.9M |
| IPO Year | 1994 | 2014 |
| Metric | JACK | TARA |
|---|---|---|
| Price | $11.17 | $4.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $21.00 | ★ $24.40 |
| AVG Volume (30 Days) | ★ 823.5K | 626.4K |
| Earning Date | 05-13-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $1,465,314,000.00 | $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.04 | N/A |
| P/E Ratio | $28.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.92 | $2.77 |
| 52 Week High | $25.34 | $7.82 |
| Indicator | JACK | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 41.14 |
| Support Level | $8.92 | $3.01 |
| Resistance Level | $20.96 | $5.53 |
| Average True Range (ATR) | 0.89 | 0.32 |
| MACD | -0.24 | -0.08 |
| Stochastic Oscillator | 18.06 | 30.29 |
Jack In The Box Inc operates quick-service restaurants and fast-casual restaurants across various states in the United States of America. Its core business includes the Jack in the Box hamburger chain, known for a broad menu that features hamburgers, tacos, sandwiches, salads, and breakfast items. The company also operates the Del Taco brand, which offers a variety of both Mexican and American favorites such as burritos and fries. These foods are available with the option of customization as per customer requirements. The company also offers catering and delivery services to its customers. Jack in the Box and Del Taco restaurant brands are the two reportable operating segments, of which, Jack in the Box generates maximum revenue for the company.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.